Market closed

Caribou Biosciences/$CRBU

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Ticker

$CRBU
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Berkeley, United States

Employees

158
Website
cariboubio.com

CRBU Metrics

BasicAdvanced
$140M
-
-$1.65
2.26
-

$140M

2.26

$8.33

$1.50

1.5M

7.383

7.178

9.055

9.474

-25.14%

-43.60%

12.113

0.5

0.5

-1.05

-66.85%

16.89%

12.67%

-21.16%

What the Analysts think about CRBU

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Caribou Biosciences stock.

CRBU Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CRBU Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

CRBU News

AllArticlesVideos
Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU

Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU

Accesswire·3 hours ago
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

Accesswire·3 hours ago
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for Investors - Contact Levi & Korsinsky

Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire·4 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRBU

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Caribou Biosciences stock?

Caribou Biosciences (CRBU) has a market cap of $140M as of January 15, 2025.

What is the P/E ratio for Caribou Biosciences stock?

The price to earnings (P/E) ratio for Caribou Biosciences (CRBU) stock is 0 as of January 15, 2025.

Does Caribou Biosciences stock pay dividends?

No, Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Caribou Biosciences dividend payment date?

Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders.

What is the beta indicator for Caribou Biosciences?

Caribou Biosciences (CRBU) has a beta rating of 2.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.